Drug:
Reaction: GENERAL PHYSICAL HEALTH DETERIORATION
20250101 - 20251231
No. 1601 - 1700
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1601 | 24886649 |
US |
||
General physical health deterioration, Ill-defined disorder, Illness, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1602 | 24886651 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1603 | 24886652 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1604 | 24886653 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1605 | 24886657 |
US |
1 | |
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1606 | 24886794 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1607 | 24885583 |
ES |
78 | 2 |
Gait disturbance, Malaise, Hyperkinesia, Device difficult to use, Pain in extremity, Gait inability, Dizziness, Mobility decreased, Intentional medical device removal by patient, Loss of personal independence in daily activities, Balance disorder, Unevaluable event, Condition aggravated, On and off phenomenon, General physical health deterioration, Posture abnormal, Therapeutic product effect decreased, Asthenia, Dizziness, Freezing phenomenon, Clumsiness, Dyskinesia, Localised infection, Dizziness, |
||||
CARBIDOPA AND LEVODOPA, CARBIDOPA AND LEVODOPA, |
||||
| 1608 | 24885684 |
US |
67 | 2 |
General physical health deterioration, |
||||
ABATACEPT, |
||||
| 1609 | 24885706 |
US |
57 | 2 |
General physical health deterioration, |
||||
ABATACEPT, |
||||
| 1610 | 24885852 |
US |
63 | 1 |
Arthralgia, General physical health deterioration, Drug ineffective, |
||||
ABATACEPT, ABATACEPT, |
||||
| 1611 | 24886148 |
DE |
30 | 1 |
Adverse drug reaction, Drug withdrawal syndrome, Lung disorder, Mucosal disorder, Metabolic disorder, Endocrine disorder, Seizure, Tremor, Amblyopia, Gait disturbance, Obstructive airways disorder, Disinhibition, Sick leave, Gastric ulcer, Conjunctivitis, Rhinorrhoea, General physical health deterioration, Dry mouth, Asthenia, Confusional state, Loss of libido, Depression, Anxiety disorder, Upper-airway cough syndrome, |
||||
VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE, |
||||
| 1612 | 24886185 |
CA |
43 | 2 |
Pneumonia, Abdominal pain upper, Anti-cyclic citrullinated peptide antibody positive, Arthralgia, Asthenia, Back injury, Blepharospasm, Blister, Breast cancer stage III, Bursitis, Confusional state, C-reactive protein increased, Contraindicated product administered, Depression, Dizziness, Drug hypersensitivity, Drug intolerance, Dry mouth, Duodenal ulcer perforation, Epilepsy, Facet joint syndrome, Fibromyalgia, Folliculitis, Gait inability, Gastrooesophageal reflux disease, General physical health deterioration, Glossodynia, Helicobacter infection, Hepatic enzyme increased, Hypercholesterolaemia, Hypertension, Hypoaesthesia, Impaired healing, Infusion related reaction, Infusion site reaction, Intentional product use issue, Irritable bowel syndrome, Liver function test increased, Lung disorder, Maternal exposure during pregnancy, Muscle injury, Muscle spasms, Muscular weakness, Musculoskeletal pain, Night sweats, Nasopharyngitis, Neck pain, Obesity, Osteoarthritis, Paraesthesia, Pemphigus, Peripheral swelling, Product use in unapproved indication, Peripheral venous disease, Synovitis, Product quality issue, Psoriatic arthropathy, Rheumatoid arthritis, Sleep disorder, Wound infection, Stomatitis, Systemic lupus erythematosus, Taste disorder, Therapeutic product effect decreased, Treatment failure, Type 2 diabetes mellitus, Urticaria, Wheezing, |
||||
SECUKINUMAB, ERENUMAB-AOOE, ERENUMAB-AOOE, ERENUMAB-AOOE, ERENUMAB-AOOE, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, CANDESARTAN, CANDESARTAN, DICLOFENAC, DICLOFENAC SODIUM, LEFLUNOMIDE, LEFLUNOMIDE, OXYCODONE, PANTOPRAZOLE, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, BOTULINUM TOXIN TYPE A, BUPRENORPHINE, CELECOXIB, CELECOXIB, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CORTISONE ACETATE, CYCLOBENZAPRINE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, ERGOCALCIFEROL, AZELAIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, ALENDRONATE SODIUM, HYDROMORPHONE HYDROCHLORIDE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, INFLIXIMAB, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, MAGNESIUM HYDROXIDE, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHYLPREDNISOLONE, MINOCYCLINE, MIRABEGRON, MIRABEGRON, NAPROXEN, NAPROXEN SODIUM, MEPOLIZUMAB, ABATACEPT, APREMILAST, PHENYLEPHRINE HYDROCHLORIDE, PHOSPHORUS, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, TOFACITINIB, |
||||
| 1613 | 24886235 |
DE |
76 | |
Pneumonitis chemical, Cough, General physical health deterioration, Oxygen saturation decreased, |
||||
OLAPARIB, ABIRATERONE ACETATE, ABIRATERONE, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, |
||||
| 1614 | 24886275 |
ES |
||
Mental impairment, General physical health deterioration, |
||||
ESKETAMINE HYDROCHLORIDE, |
||||
| 1615 | 24881023 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 1616 | 24881346 |
US |
50 | 2 |
Abdominal pain upper, Feeding disorder, Dehydration, Chest discomfort, Headache, Dizziness, Blood pressure decreased, General physical health deterioration, |
||||
TREPROSTINIL, TREPROSTINIL, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, OXYCODONE HYDROCHLORIDE, OXYCODONE, SPIRONOLACTONE, OXYGEN, 0XYGEN, |
||||
| 1617 | 24881443 |
US |
38 | 2 |
General physical health deterioration, |
||||
ABATACEPT, |
||||
| 1618 | 24881730 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1619 | 24881812 |
CA |
43 | 2 |
Pemphigus, Abdominal discomfort, Vomiting, Arthralgia, Rash, Synovitis, Wound infection, Alopecia, Glossodynia, Depression, Joint range of motion decreased, Type 2 diabetes mellitus, Swelling, Drug intolerance, Fibromyalgia, Diarrhoea, Maternal exposure during pregnancy, Wound, Blister, Anti-cyclic citrullinated peptide antibody positive, Live birth, Hand deformity, Wheezing, General physical health deterioration, Pericarditis, Duodenal ulcer perforation, Breast cancer stage III, Intentional product use issue, Systemic lupus erythematosus, Helicobacter infection, |
||||
DICLOFENAC SODIUM, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE, LAMOTRIGINE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, NAPROXEN, NAPROXEN SODIUM, NAPROXEN, NAPROXEN SODIUM, OXYCODONE HYDROCHLORIDE, OXYCODONE, QUETIAPINE FUMARATE, QUETIAPINE, QUETIAPINE FUMARATE, QUETIAPINE, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, TOPIRAMATE, TOPIRAMATE SPINKLE, TOPIRAMATE, TOPIRAMATE SPINKLE, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ERENUMAB-AOOE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, CANDESARTAN, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 1620 | 24881930 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1621 | 24881962 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 1622 | 24881982 |
US |
2 | |
General physical health deterioration, |
||||
SPIRONOLACTONE, SULFAMETHOXAZOLE AND TRIMETHOPRIM, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, SILDENAFIL CITRATE, SILDENAFIL, AZELASTINE HYDROCHLORIDE, AZELASTINE, ERGOCALCIFEROL, ESOMEPRAZOLE MAGNESIUM, DULOXETINE HYDROCHLORIDE, ALBUTEROL SULFATE, ENOXAPARIN SODIUM, OIL, BIOTIN, HAIR, COLLAGENASE SANTYL, PREDNISONE, BUSPIRONE HYDROCHLORIDE, MONTELUKAST SODIUM, MONTELUKAST, CALCIUM, OXYGEN, 0XYGEN, CETIRIZINE HYDROCHLORIDE, LOSARTAN POTASSIUM, LOSARTAN, VITAMIN C, CYCLOSPORINE, |
||||
| 1623 | 24882057 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 1624 | 24882070 |
CA |
43 | 2 |
Abdominal pain, Abdominal pain upper, Abdominal discomfort, Alopecia, Anti-cyclic citrullinated peptide antibody positive, Anxiety, Arthralgia, Arthropathy, Asthenia, Asthma, Autoimmune disorder, Back injury, Blepharospasm, Blister, Blood cholesterol increased, Breast cancer stage III, Bursitis, C-reactive protein abnormal, C-reactive protein increased, Condition aggravated, Confusional state, Contusion, Decreased appetite, Deep vein thrombosis postoperative, Depression, Diarrhoea, Discomfort, Dislocation of vertebra, Dizziness, Drug hypersensitivity, Dry mouth, Duodenal ulcer perforation, Dyspnoea, Epilepsy, Facet joint syndrome, Fatigue, Fibromyalgia, Folliculitis, Gait inability, Gastrointestinal disorder, Gastrooesophageal reflux disease, General physical health deterioration, Glossodynia, Hand deformity, Headache, Helicobacter infection, Hepatic enzyme increased, Hypercholesterolaemia, Hypertension, Hypoaesthesia, Impaired healing, Infection, Inflammation, Infusion related reaction, Infusion site reaction, Injury, Irritable bowel syndrome, Joint range of motion decreased, Joint swelling, Lip dry, Liver function test increased, Liver injury, Lower respiratory tract infection, Lung disorder, Memory impairment, Migraine, Mobility decreased, Muscle injury, Muscle spasms, Muscular weakness, Musculoskeletal pain, Nail disorder, Nasopharyngitis, Nausea, Neck pain, Night sweats, Obesity, Onychomadesis, Osteoarthritis, Pain, Pain in extremity, Paraesthesia, Pemphigus, Pericarditis, Peripheral swelling, Peripheral venous disease, Psoriatic arthropathy, Rash, Rheumatoid arthritis, Stomatitis, Swelling, Synovitis, Systemic lupus erythematosus, Taste disorder, Type 2 diabetes mellitus, Urticaria, Vomiting, Weight increased, Wheezing, Wound, Wound infection, Adverse drug reaction, Adverse event, Live birth, Drug intolerance, Exposure during pregnancy, Maternal exposure during pregnancy, Drug ineffective, Treatment failure, Therapeutic product effect incomplete, Therapeutic product effect decreased, Intentional product use issue, Contraindicated product administered, Off label use, Product quality issue, Product use in unapproved indication, Product use issue, Product label confusion, Coeliac disease, Dyspepsia, Grip strength decreased, Insomnia, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, ERENUMAB-AOOE, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, SECUKINUMAB, SECUKINUMAB, LAMOTRIGINE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, MEPOLIZUMAB, TRETINOIN, |
||||
| 1625 | 24882156 |
AT |
69 | 1 |
Metastases to lung, General physical health deterioration, |
||||
PANITUMUMAB, |
||||
| 1626 | 24882192 |
US |
52 | 2 |
General physical health deterioration, Pain, |
||||
ABATACEPT, |
||||
| 1627 | 24882604 |
US |
69 | 2 |
Dyspnoea at rest, Syncope, Bendopnoea, Pneumonia, Syncope, Dyspnoea, Dyspnoea exertional, Chest pain, Fatigue, Dizziness, Peripheral swelling, Joint swelling, Weight abnormal, Swelling, Fatigue, Dizziness, Hypotension, Dizziness, General physical health deterioration, Decreased activity, |
||||
RIOCIGUAT, RIOCIGUAT, RIOCIGUAT, AMBRISENTAN, |
||||
| 1628 | 24883194 |
FR |
||
Endocarditis staphylococcal, Multiple organ dysfunction syndrome, Behavioural addiction, General physical health deterioration, Hypoalbuminaemia, Aspergilloma, Blood culture positive, Deep vein thrombosis, Hypoxia, Hypotension, Pyrexia, Drug abuse, Intentional product misuse, Inappropriate schedule of product administration, |
||||
BUPRENORPHINE, BUPRENORPHINE, ZOLPIDEM TARTRATE, RISPERIDONE, PROPRANOLOL HYDROCHLORIDE, TOBACCO LEAF, |
||||
| 1629 | 24883546 |
US |
78 | 2 |
Sepsis, Fall, General physical health deterioration, |
||||
BEVACIZUMAB, |
||||
| 1630 | 24883729 |
US |
1 | |
General physical health deterioration, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 1631 | 24883760 |
BR |
63 | 1 |
General physical health deterioration, Muscular weakness, Mobility decreased, Fatigue, Traumatic lung injury, Malaise, Device physical property issue, Dyspnoea, |
||||
ALBUTEROL SULFATE, ALBUTEROL, ENALAPRIL, FUROSEMIDE, |
||||
| 1632 | 24883960 |
TR |
24 | 1 |
Loss of consciousness, Thrombocytopenia, Hypotension, Pyrexia, Subcutaneous abscess, Nausea, Feeding disorder, Haemoglobin decreased, Hypoalbuminaemia, Blood folate decreased, Vitamin B12 decreased, Oesophageal candidiasis, Chloroma, Asthenia, Staphylococcal abscess, Depressed mood, Increased appetite, Insomnia, Livedo reticularis, Dry skin, Transaminases increased, Hepatic steatosis, Pityriasis rosea, Myalgia, Muscular weakness, Blood electrolytes decreased, Weight increased, Muscular weakness, Mobility decreased, Alopecia, Depressive symptom, Anxiety, Pruritus, General physical health deterioration, Blood creatine phosphokinase increased, Off label use, |
||||
GILTERITINIB, GILTERITINIB, GILTERITINIB, GILTERITINIB, GILTERITINIB, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, |
||||
| 1633 | 24884215 |
NL |
||
General physical health deterioration, Gastrointestinal anastomotic leak, Vascular device infection, Ileal stenosis, Crohn^s disease, Colitis ulcerative, Inflammatory bowel disease, Dermatomyositis, Anal abscess, Post procedural infection, Postoperative wound infection, Abdominal abscess, Urinary tract infection, Pyrexia, Pneumonia, Therapy non-responder, |
||||
ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, |
||||
| 1634 | 24884232 |
CA |
2 | |
Abdominal discomfort, Anti-cyclic citrullinated peptide antibody positive, Arthralgia, Arthropathy, Blister, Condition aggravated, Confusional state, Contraindicated product administered, Contusion, Discomfort, Duodenal ulcer perforation, Dyspnoea, Fatigue, Folliculitis, Gastrointestinal disorder, General physical health deterioration, Glossodynia, Hand deformity, Helicobacter infection, Hepatic enzyme increased, Ill-defined disorder, Impaired healing, Infusion related reaction, Injury, Irritable bowel syndrome, Joint swelling, Lower respiratory tract infection, Muscle injury, Nasopharyngitis, Pemphigus, Pericarditis, Peripheral swelling, Pyrexia, Rheumatoid arthritis, Sinusitis, Sleep disorder, Sleep disorder due to general medical condition, insomnia type, Synovitis, Systemic lupus erythematosus, Wound, Weight increased, Stomatitis, Alopecia, Swelling, Hypersensitivity, Infection, Insomnia, Pain, Pruritus, Rash, |
||||
DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DESOXIMETASONE, DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE TABLETS, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, ALENDRONATE SODIUM, APREPITANT, LEFLUNOMIDE, CETRIMIDE, CHLORHEXIDINE GLUCONATE, ANTISEPTIC SKIN CLEANSER, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, HYDROCORTISONE ACETATE, ETANERCEPT, FOLIC ACID, FOSAPREPITANT, FOSAPREPITANT DIMEGLUMINE, ADALIMUMAB, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE SULFATE, ISOPROPYL ALCOHOL, 70%ISOPROPYL ALCOHOL, ALCOHOL PREP PADS, ALCOHOL, ISOPROPYL ALCOHOL SPRAY, LEFLUNOMIDE, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, ABATACEPT, OXYCODONE, PREDNISONE, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, INFLIXIMAB, RITUXIMAB, GOLIMUMAB, USTEKINUMAB, SULFASALAZINE, SULFASALAZINE, TOFACITINIB, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, PANTOPRAZOLE, |
||||
| 1635 | 24884400 |
PR |
79 | 2 |
Dementia Alzheimer^s type, General physical health deterioration, Gait disturbance, Dizziness, Fall, Musculoskeletal chest pain, Hernia, |
||||
TERIFLUNOMIDE, TERIFLUNOMIDE, TERIFLUNOMIDE, MEMANTINE, MEMANTINE HYDROCHLORIDE, QUETIAPINE, QUETIAPINE EXTENDED-RELEASE, |
||||
| 1636 | 24884577 |
US |
5 | 2 |
Mental disorder, General physical health deterioration, Dermatitis atopic, Ocular hyperaemia, Eye irritation, Rash, Erythema, Extra dose administered, |
||||
DUPILUMAB, |
||||
| 1637 | 24885016 |
US |
42 | 2 |
General physical health deterioration, Injection site rash, Injection site pain, Incorrect dose administered, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1638 | 24885165 |
CA |
65 | 2 |
Septic shock, Anaemia of chronic disease, Confusional state, General physical health deterioration, Hypotension, Acute kidney injury, Pericarditis, Nausea, Fatigue, Asthenia, Adrenal insufficiency, Hypophysitis, |
||||
PEMBROLIZUMAB, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, INDAPAMIDE, PACLITAXEL, |
||||
| 1639 | 24885179 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1640 | 24885364 |
US |
||
General physical health deterioration, Influenza, Ill-defined disorder, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1641 | 24885527 |
NL |
72 | 1 |
General physical health deterioration, Dementia, On and off phenomenon, Stoma site pain, Stoma site erythema, Device issue, Speech disorder, Muscle rigidity, Stoma site infection, Stoma site reaction, |
||||
LACTULOSE, |
||||
| 1642 | 24876138 |
US |
||
Lung disorder, Haemoptysis, Cardiac disorder, Breathing-related sleep disorder, Obstructive airways disorder, Illness, General physical health deterioration, Productive cough, Drug ineffective, Hospice care, |
||||
BENRALIZUMAB, BENRALIZUMAB, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, TEZEPELUMAB-EKKO, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, NITROGLYCERIN, PREDNISONE, DUPILUMAB, MEPOLIZUMAB, |
||||
| 1643 | 24876253 |
DE |
72 | 2 |
Death, General physical health deterioration, |
||||
| 1644 | 24876639 |
US |
1 | |
General physical health deterioration, |
||||
| 1645 | 24876768 |
JP |
8 | 1 |
General physical health deterioration, Decreased appetite, |
||||
ENFORTUMAB VEDOTIN, |
||||
| 1646 | 24877381 |
DE |
||
Generalised tonic-clonic seizure, Thinking abnormal, Seizure, Suicidal ideation, Bradykinesia, Electroencephalogram abnormal, General physical health deterioration, Polydipsia, Nightmare, Depression, Tremor, Rash, Panic attack, Drug ineffective, |
||||
ESCITALOPRAM, ESCITALOPRAM OXALATE, ESCITSLOPRAM, LACOSAMIDE, ZONISAMIDE, LEVETIRACETAM, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, LEVETIRACETAM IN SODIUM CHLORIDE, OXCARBAZEPINE, ETHOSUXIMIDE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, |
||||
| 1647 | 24877630 |
US |
2 | |
Death, Tumour lysis syndrome, Respiratory failure, Metastases to central nervous system, Unresponsive to stimuli, Haemophagocytic lymphohistiocytosis, Diffuse large B-cell lymphoma recurrent, Shock, Multiple organ dysfunction syndrome, Coagulopathy, General physical health deterioration, |
||||
RITUXIMAB, PREDNISONE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 1648 | 24877704 |
CA |
40 | 2 |
Abdominal discomfort, Abdominal distension, Drug-induced liver injury, Folliculitis, Hand deformity, Insomnia, Pruritus, Psoriatic arthropathy, Rheumatoid arthritis, Systemic lupus erythematosus, Blister, C-reactive protein abnormal, Dyspnoea, Finger deformity, Lower respiratory tract infection, Malaise, Product label confusion, Rash, Stomatitis, Synovitis, Wound, Arthropathy, Coeliac disease, Gait inability, Grip strength decreased, Hypertension, Inflammation, Liver function test increased, Musculoskeletal stiffness, Type 2 diabetes mellitus, Anti-cyclic citrullinated peptide antibody positive, Confusional state, C-reactive protein increased, Drug hypersensitivity, Headache, Joint swelling, Onychomadesis, Pain, Pneumonia, Swelling, Alopecia, Blood cholesterol increased, Glossodynia, Hypersensitivity, Infusion related reaction, Injury, Pain in extremity, Pericarditis, Back injury, General physical health deterioration, Hepatic enzyme increased, Impaired healing, Nausea, Vomiting, Contusion, Duodenal ulcer perforation, Fall, Gastrointestinal disorder, Helicobacter infection, Hepatitis, Ill-defined disorder, Muscular weakness, Onychomycosis, Overdose, Rheumatic fever, Dyspepsia, Fatigue, Injection site reaction, Mobility decreased, Nail disorder, Neck pain, Pemphigus, Sleep disorder, |
||||
HYDROXYCHLOROQUINE SULFATE, METHOTREXATE, METHOTREXATE SODIUM, USTEKINUMAB, SULFASALAZINE, TOFACITINIB, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, TOCILIZUMAB, LEFLUNOMIDE, PREDNISONE, LEFLUNOMIDE, AZATHIOPRINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CERTOLIZUMAB PEGOL, SECUKINUMAB, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, ETANERCEPT, DESOXIMETASONE, ETANERCEPT, FOLIC ACID, ALENDRONATE SODIUM, GOLD, ADALIMUMAB, HYDROCORTISONE ACETATE, INFLIXIMAB, LEFLUNOMIDE, METHYLPREDNISOLONE, MINOCYCLINE, ABATACEPT, APREMILAST, PREDNISONE, INFLIXIMAB, RITUXIMAB, SULFASALAZINE, GOLIMUMAB, NAPROXEN, NAPROXEN SODIUM, METHOTREXATE, METHOTREXATE SODIUM, GOLIMUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, LEFLUNOMIDE, LEFLUNOMIDE, PREDNISONE, CERTOLIZUMAB PEGOL, DESOXIMETASONE, ETANERCEPT, ETANERCEPT, ADALIMUMAB, HYDROCORTISONE ACETATE, HYDROXYCHLOROQUINE SULFATE, LEFLUNOMIDE, LEFLUNOMIDE, METHOTREXATE, METHOTREXATE SODIUM, ABATACEPT, ABATACEPT, PREDNISONE, PREDNISONE, INFLIXIMAB, INFLIXIMAB, RITUXIMAB, SULFASALAZINE, TOFACITINIB, TOFACITINIB, METHOTREXATE, METHOTREXATE SODIUM, PREDNISONE, PREDNISONE, RITUXIMAB, |
||||
| 1649 | 24878030 |
CA |
41 | 2 |
Anxiety, Blood pressure fluctuation, Blood pressure increased, Condition aggravated, Depression, Frustration tolerance decreased, General physical health deterioration, Hepatic enzyme increased, Illness, Inappropriate schedule of product administration, Loss of consciousness, Injection site rash, Migraine, Stress, Urticaria, Pruritus, Hypersensitivity, Rash, Anaphylactic reaction, Heart rate increased, Hypotension, |
||||
ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, OMALIZUMAB, OMALIZUMAB, EPINEPHRINE, ADRENALINUM, IBUPROFEN SODIUM, IBUPROFEN, IBUPROFEN TABLETS, COATED, IBUPROFEN TABLET COATED, DICLOFENAC, DICLOFENAC SODIUM, DIPHENHYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE, FAMOTIDINE, LORAZEPAM, RIZATRIPTAN BENZOATE, METHYLPREDNISOLONE, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, RIZATRIPTAN BENZOATE, |
||||
| 1650 | 24878040 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 1651 | 24878526 |
CA |
2 | |
Abdominal discomfort, Anti-cyclic citrullinated peptide antibody positive, Arthralgia, Arthropathy, Blister, Condition aggravated, Confusional state, Contusion, Discomfort, Duodenal ulcer perforation, Dyspnoea, Fatigue, Folliculitis, General physical health deterioration, Glossodynia, Hand deformity, Helicobacter infection, Hepatic enzyme increased, Ill-defined disorder, Impaired healing, Infusion related reaction, Injury, Pericarditis, Systemic lupus erythematosus, Rheumatoid arthritis, Infection, Gastrointestinal disorder, Hypersensitivity, Alopecia, Contraindicated product administered, |
||||
ALENDRONATE SODIUM, ALENDRONATE SODIUM, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, LEFLUNOMIDE, LEFLUNOMIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, HYDROCORTISONE, HYDROCORTISONE, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, APREPITANT, FOSAPREPITANT DIMEGLUMINE, APREPITANT, FOSAPREPITANT DIMEGLUMINE, FOLIC ACID, FOLIC ACID, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, SARILUMAB, SARILUMAB, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, PREDNISONE, PREDNISONE, PREDNISONE, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, |
||||
| 1652 | 24878624 |
CO |
73 | 1 |
Peripheral swelling, Phlebitis, Protein urine present, Swelling, Pain in extremity, General physical health deterioration, Insomnia, Pain, |
||||
TAFAMIDIS, |
||||
| 1653 | 24878727 |
US |
1 | |
Mental fatigue, Quality of life decreased, General physical health deterioration, Rash, |
||||
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, RELUGOLIX, |
||||
| 1654 | 24878740 |
US |
||
General physical health deterioration, Illness, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1655 | 24878853 |
US |
74 | 2 |
Death, General physical health deterioration, |
||||
AXITINIB, |
||||
| 1656 | 24878856 |
DE |
79 | 2 |
Leukopenia, Chronic kidney disease, Blood creatinine increased, Asthenia, Nephrolithiasis, Glomerular filtration rate decreased, General physical health deterioration, Atrial fibrillation, Electrocardiogram QT prolonged, Thrombocytopenia, Nausea, Vomiting, Neutropenia, Anaemia, Acute kidney injury, Cardiac failure congestive, Osteoarthritis, Osteoarthritis, Renal impairment, Hyponatraemia, Concomitant disease aggravated, Hypertension, Cardiac failure, Urinary retention, Cardiac failure, Blood glucose increased, Eastern Cooperative Oncology Group performance status worsened, Bronchitis, Cystitis, Infection, Blood thyroid stimulating hormone increased, C-reactive protein increased, Pleural effusion, Urinary tract infection, Blood pressure increased, Oedema peripheral, Dry skin, Dyspnoea, Product use in unapproved indication, |
||||
PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, LETROZOLE, LETROZOLE TABLETS, LETROZOLE, LETROZOLE TABLETS, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, CALCIUM, |
||||
| 1657 | 24878891 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1658 | 24878892 |
JP |
85 | 1 |
Pneumonia bacterial, General physical health deterioration, |
||||
PEMBROLIZUMAB, ENFORTUMAB VEDOTIN, |
||||
| 1659 | 24879627 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 1660 | 24879654 |
62 | 2 | |
COVID-19, Oxygen saturation decreased, General physical health deterioration, Peripheral swelling, Joint swelling, Peripheral swelling, |
||||
MACITENTAN, TREPROSTINIL, |
||||
| 1661 | 24879677 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1662 | 24879724 |
CA |
1 | |
Decubitus ulcer, Prostate cancer metastatic, General physical health deterioration, Metastases to bone, Diarrhoea, Anaemia, Blood alkaline phosphatase increased, |
||||
VEDOLIZUMAB, PREDNISONE, |
||||
| 1663 | 24879793 |
CA |
43 | 2 |
Abdominal discomfort, Folliculitis, Walking aid user, Blepharospasm, C-reactive protein increased, Infection, Peripheral swelling, Mobility decreased, Musculoskeletal stiffness, Dry mouth, Chest pain, Delirium, Pyrexia, Sleep disorder, Osteoarthritis, Discomfort, Pustular psoriasis, Facet joint syndrome, Dyspepsia, Breast cancer stage III, Muscle injury, Asthenia, Decreased appetite, Swelling, Synovitis, Rash, Pain in extremity, Nail disorder, Injury, Pulmonary fibrosis, Pericarditis, Pneumonia, Duodenal ulcer perforation, Depression, Breast cancer stage II, Stomatitis, Myositis, Knee arthroplasty, Hypersensitivity, Contusion, Dizziness, Liver injury, Diarrhoea, Hand deformity, Peripheral venous disease, Ill-defined disorder, Hip arthroplasty, Bursitis, Malaise, Off label use, Oedema, Memory impairment, Psoriatic arthropathy, Amnesia, Rash vesicular, Dislocation of vertebra, Musculoskeletal pain, Pruritus, Vomiting, Wound, General physical health deterioration, Rheumatic fever, Nasopharyngitis, Swollen joint count increased, Joint swelling, Alopecia, Condition aggravated, Nausea, Gait inability, Urticaria, Hypercholesterolaemia, Hepatic enzyme increased, Wheezing, Night sweats, Arthralgia, Systemic lupus erythematosus, Migraine, Pain, Lower respiratory tract infection, Helicobacter infection, Gastrointestinal disorder, Weight decreased, Drug intolerance, Taste disorder, Adverse event, Impaired healing, Maternal exposure during pregnancy, Abdominal pain, Lip dry, Type 2 diabetes mellitus, Epilepsy, X-ray abnormal, Psoriasis, Fibromyalgia, Inflammation, Joint range of motion decreased, Paraesthesia, Arthropathy, Drug ineffective, Hypertension, Fluid retention, Subcutaneous drug absorption impaired, Confusional state, Sleep disorder due to a general medical condition, Intentional product use issue, Adjustment disorder with depressed mood, Back disorder, Hypoaesthesia, Oedema peripheral, Fatigue, Gait disturbance, Wound infection, Rheumatoid arthritis, Gastrooesophageal reflux disease, Lung disorder, Obesity, Drug hypersensitivity, Infusion related reaction, Adverse drug reaction, Pemphigus, Sinusitis, Grip strength decreased, Dyspnoea, Blister, Anti-cyclic citrullinated peptide antibody positive, Weight increased, Product quality issue, Muscle spasms, Disability, Abdominal pain upper, Glossodynia, Headache, Blood cholesterol increased, General symptom, Rheumatoid factor positive, Irritable bowel syndrome, C-reactive protein abnormal, |
||||
METHOTREXATE, METHOTREXATE SODIUM, TOFACITINIB, TOFACITINIB, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, LISINOPRIL, VITAMIN A, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, SULFASALAZINE, TOPIRAMATE, ERGOCALCIFEROL, LORAZEPAM, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, LISINOPRIL, LAMOTRIGINE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, ASIAN GINSENG, CALCIUM, LANSOPRAZOLE, LISINOPRIL, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, INFLIXIMAB, INFLIXIMAB, CALCIUM CARBONATE, THIAMINE HYDROCHLORIDE, USTEKINUMAB, GOLIMUMAB, GOLIMUMAB, GOLIMUMAB, GOLIMUMAB, ETANERCEPT, ETANERCEPT, ETANERCEPT, NAPROXEN SODIUM, NAPROXEN SODIUM, COATED TABLETS, NAPROXEN SODIUM TABLET, COATED, RANITIDINE HYDROCHLORIDE, ERGOCALCIFEROL, RAMIPRIL, METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE, DICLOFENAC, DICLOFENAC SODIUM, TOPIRAMATE, TOPIRAMATE SPINKLE, TOPIRAMATE, TOPIRAMATE SPINKLE, TOPIRAMATE, TOPIRAMATE SPINKLE, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, THIAMINE HYDROCHLORIDE, RIBOFLAVIN 5 PHOSPHATE SODIUM, DEXPANTHENOL AND NIACINAMIDE, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, ISOPROPYL ALCOHOL, 70%ISOPROPYL ALCOHOL, ALCOHOL PREP PADS, ALCOHOL, ISOPROPYL ALCOHOL SPRAY, ISOPROPYL ALCOHOL, 70%ISOPROPYL ALCOHOL, ALCOHOL PREP PADS, ALCOHOL, ISOPROPYL ALCOHOL SPRAY, CAFFEINE CITRATE, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, LORAZEPAM, ADALIMUMAB, ADALIMUMAB, CHLORHEXIDINE GLUCONATE, ANTISEPTIC SKIN CLEANSER, NAPROXEN, NAPROXEN SODIUM, NAPROXEN, NAPROXEN SODIUM, NICOTINAMIDE, ABATACEPT, ABATACEPT, ABATACEPT, ABATACEPT, ABATACEPT, MIRABEGRON, CYANOCOBALAMIN, APREMILAST, APREMILAST, TRAMADOL HYDROCHLORIDE, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, VEDOLIZUMAB, FOLIC ACID, QUETIAPINE FUMARATE, QUETIAPINE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, MEPOLIZUMAB, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, TOFACITINIB, TOFACITINIB, TOFACITINIB, TOFACITINIB, LANSOPRAZOLE, RISEDRONATE SODIUM, PREDNISONE, |
||||
| 1664 | 24879894 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1665 | 24879911 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1666 | 24880051 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1667 | 24880180 |
DE |
57 | 2 |
Multiple organ dysfunction syndrome, Melaena, Mouth haemorrhage, Gingival hypertrophy, Hepatitis E, Plasma cell myeloma, Renal failure, Pancytopenia, General physical health deterioration, |
||||
DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, ELOTUZUMAB, ELOTUZUMAB, ISATUXIMAB, CARFILZOMIB, DARATUMUMAB, BORTEZOMIB FOR INJECTION, BORTEZOMIB, |
||||
| 1668 | 24880234 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1669 | 24880271 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1670 | 24880552 |
CA |
2 | |
Large intestine perforation, General physical health deterioration, Hypoaesthesia, Swollen tongue, Hypoaesthesia oral, Lip swelling, |
||||
ADALIMUMAB-ADAZ, ADALIMUMAB-ADAZ, ADALIMUMAB-ADAZ, |
||||
| 1671 | 24880605 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1672 | 24880681 |
CH |
77 | 1 |
General physical health deterioration, |
||||
| 1673 | 24890683 |
|||
Fall, Lower limb fracture, Multiple sclerosis relapse, Hot flush, Cerebral disorder, General physical health deterioration, |
||||
OCRELIZUMAB, |
||||
| 1674 | 24871335 |
US |
2 | |
Coma, Pneumonia, Noninfective encephalitis, Cardiac disorder, Renal impairment, Haemoglobin decreased, Withdrawal syndrome, General physical health deterioration, |
||||
OLANZAPINE, BUPROPION HYDROCHLORIDE, |
||||
| 1675 | 24871336 |
JP |
64 | 1 |
Death, Pneumonia, Hypoglycaemia, Altered state of consciousness, General physical health deterioration, Communication disorder, Decreased activity, Bedridden, Soliloquy, |
||||
OLANZAPINE, RISPERIDONE, |
||||
| 1676 | 24871530 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1677 | 24871909 |
US |
1 | |
Disease progression, General physical health deterioration, Pain, Muscle spasms, Fatigue, Lethargy, Mobility decreased, Hypersomnia, Nausea, |
||||
EDARAVONE, EDARAVONE, RILUZOLE, |
||||
| 1678 | 24871922 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1679 | 24872084 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1680 | 24872221 |
US |
60 | 2 |
General physical health deterioration, |
||||
ABATACEPT, |
||||
| 1681 | 24872245 |
DE |
1 | |
Suicidal ideation, Thinking abnormal, Seizure, Generalised tonic-clonic seizure, Bradykinesia, Tremor, Electroencephalogram abnormal, Rash, Drug ineffective, General physical health deterioration, Polydipsia, Panic attack, Nightmare, Depression, |
||||
ESCITALOPRAM, ESCITALOPRAM OXALATE, ESCITSLOPRAM, LACOSAMIDE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, LEVETIRACETAM, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, LEVETIRACETAM IN SODIUM CHLORIDE, ZONISAMIDE, ETHOSUXIMIDE, OXCARBAZEPINE, |
||||
| 1682 | 24872294 |
US |
85 | 2 |
General physical health deterioration, |
||||
TREPROSTINIL, TREPROSTINIL, FUROSEMIDE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, DULOXETINE HYDROCHLORIDE, DULOXETIN HYDROCHLORIDE, DULOXETINE, OXYGEN, 0XYGEN, PREDNISONE, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 1683 | 24872346 |
FR |
92 | 2 |
Vomiting, General physical health deterioration, |
||||
DOXYCYCLINE, DOXYCYCLINE HYCLATE, |
||||
| 1684 | 24872428 |
IT |
80 | 1 |
Haemorrhage urinary tract, Respiratory failure, General physical health deterioration, |
||||
| 1685 | 24872669 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1686 | 24872728 |
US |
||
COVID-19, General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1687 | 24872731 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1688 | 24872920 |
US |
1 | |
General physical health deterioration, |
||||
CILTACABTAGENE AUTOLEUCEL, |
||||
| 1689 | 24873073 |
SE |
90 | 1 |
Depressed level of consciousness, General physical health deterioration, |
||||
QUETIAPINE, QUETIAPINE EXTENDED-RELEASE, |
||||
| 1690 | 24873323 |
FR |
70 | 1 |
General physical health deterioration, Diarrhoea, |
||||
FRUQUINTINIB, |
||||
| 1691 | 24873775 |
US |
1 | |
Illness, General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1692 | 24874048 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1693 | 24874423 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1694 | 24874592 |
CN |
1 | |
General physical health deterioration, Feeding disorder, Decreased appetite, Asthenia, |
||||
IXAZOMIB, |
||||
| 1695 | 24874683 |
CA |
42 | 1 |
Acute kidney injury, Ascites, Bacteraemia, Bacterial infection, Bone marrow failure, Dyspnoea, Febrile neutropenia, Flank pain, General physical health deterioration, Hepatomegaly, Periportal oedema, Platelet transfusion, Pneumonia, Pyrexia, Respiratory failure, Sepsis, Thrombocytopenia, Venoocclusive disease, |
||||
CYTARABINE, GEMTUZUMAB OZOGAMICIN, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, CLINDAMYCIN PHOSPHATE, CLINDAMYCIN, DIMENHYDRINATE, HALOPERIDOL, HALOPERIDOL LACTATE, LEVOTHYROXINE, MAGNESIUM SULFATE, MAGNESIUM SULFATE HEPTAHYDRATE, MAGNESIUM SULFATE IN WATER FOR, METHYLPREDNISOLONE, MORPHINE, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, PANTOPRAZOLE, PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, POLYETHYLENE GLYCOL (3350), POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 400, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, POTASSIUM PHOSPHATE, MONOBASIC AND POTASSIUM PHOSPHATE, DIBASIC, POTASSIUM PHOSPHATES, POTASSIUM PHOSPHATES IN SODIUM CHLORIDE, POTASSIUM PHOSPHATE, MONOBASIC POTASSIUM PHOSPHATE, DIBASIC, POTASSIUM PHOSPHATE, MONOBASIC POTASSIUM PHOSPHATE, DIBASIC INJECTION,, MONOBASIC POTASSIUM PHOSPHATE AND DIBASIC POTASSIUM PHOSPHATE, POTASSIUM PHOSPHATE, PROCHLORPERAZINE, SODIUM PHOSPHATE, URSODIOL, URSOSIOL, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN, |
||||
| 1696 | 24874764 |
CA |
1 | |
Testicular disorder, Hernia, Arthralgia, General physical health deterioration, Gait disturbance, Pain in extremity, Stress, Weight decreased, Grief reaction, |
||||
ADALIMUMAB-ADAZ, METHOTREXATE, METHOTREXATE SODIUM, SEMAGLUTIDE, |
||||
| 1697 | 24874827 |
54 | 2 | |
General physical health deterioration, Immunoglobulins decreased, Drug ineffective, Therapy interrupted, |
||||
AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE, GALCANEZUMAB-GNLM, ESCITALOPRAM, ESCITALOPRAM OXALATE, ESCITSLOPRAM, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
| 1698 | 24874873 |
US |
||
Diabetes mellitus, General physical health deterioration, Hypertension, |
||||
RELUGOLIX, RELUGOLIX, |
||||
| 1699 | 24874941 |
US |
||
Illness, Malaise, General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 1700 | 24875031 |
US |
52 | 2 |
General physical health deterioration, Pain, |
||||
ABATACEPT, UPADACITINIB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28